Clovis Oncology (NASDAQ:CLVS) had its target price decreased by analysts at SunTrust Banks to $28.00 in a report issued on Monday, The Fly reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ price target suggests a potential upside of 32.01% from the company’s current price.
Other analysts also recently issued research reports about the stock. HC Wainwright started coverage on shares of Clovis Oncology in a report on Wednesday, February 13th. They set a “buy” rating and a $40.00 price target on the stock. Zacks Investment Research raised shares of Clovis Oncology from a “sell” rating to a “hold” rating in a report on Thursday, January 24th. BidaskClub raised shares of Clovis Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, January 9th. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $27.00 price target on shares of Clovis Oncology in a report on Wednesday, February 27th. Finally, ValuEngine raised shares of Clovis Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 1st. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company’s stock. Clovis Oncology presently has a consensus rating of “Hold” and a consensus price target of $43.44.
Shares of NASDAQ CLVS opened at $21.21 on Monday. The company has a current ratio of 4.55, a quick ratio of 4.34 and a debt-to-equity ratio of 3.93. The stock has a market cap of $1.09 billion, a PE ratio of -3.00 and a beta of 2.08. Clovis Oncology has a 52-week low of $11.50 and a 52-week high of $55.15.
In related news, Director James C. Blair sold 17,056 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $27.79, for a total value of $473,986.24. Following the transaction, the director now owns 13,439 shares of the company’s stock, valued at $373,469.81. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Lindsey Rolfe sold 1,731 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $29.29, for a total transaction of $50,700.99. Following the completion of the transaction, the insider now directly owns 16,497 shares in the company, valued at approximately $483,197.13. The disclosure for this sale can be found here. In the last three months, insiders sold 20,782 shares of company stock worth $576,755. 10.20% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of Clovis Oncology by 2.4% in the third quarter. Vanguard Group Inc. now owns 4,445,064 shares of the biopharmaceutical company’s stock worth $130,551,000 after buying an additional 104,655 shares during the last quarter. KBC Group NV lifted its holdings in Clovis Oncology by 30.7% during the fourth quarter. KBC Group NV now owns 315,958 shares of the biopharmaceutical company’s stock valued at $5,675,000 after purchasing an additional 74,229 shares in the last quarter. Teachers Advisors LLC lifted its holdings in Clovis Oncology by 0.9% during the third quarter. Teachers Advisors LLC now owns 144,561 shares of the biopharmaceutical company’s stock valued at $4,246,000 after purchasing an additional 1,278 shares in the last quarter. Virtus ETF Advisers LLC lifted its holdings in Clovis Oncology by 80.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 30,876 shares of the biopharmaceutical company’s stock valued at $555,000 after purchasing an additional 13,775 shares in the last quarter. Finally, Sofinnova Investments Inc. purchased a new position in Clovis Oncology during the fourth quarter valued at approximately $5,168,000.
Clovis Oncology Company Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Recommended Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.